Incidence of bacterial infections with multidrug resistance is increasing rapidly, generating the need for novel, broad-spectrum carbapenem-based antibiotics for the treatment of various bacterial infections. Broad-spectrum carbapenem-based antibiotics such as tebipenem (Spero Therapeutics Inc.) and sulopenem (Iterum Therapeutics Inc.) are at late stage clinical development with expected launch of both in 2020 – 2021. Multidrug resistance to currently marketed carbapenem-based antibiotics is largely prevalent in the world. Also, expiry of patent for ertapenem is expected to offer new avenues for market growth in regulated as well as non-regulated carbapenem-based antibiotics market where its adoption & availability are comparatively limited. On the back of these factors, the global carbapenem-based antibiotics market is estimated to reach a valuation of US$1.8 Bn by 2029.
For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4425
Key Takeaways of Carbapenem-based Antibiotics Market Study
- Larger patient pools and launch of novel products for the treatment of bacterial infections are expected to shape the carbapenem-based antibiotics market landscape.
- Increasing prevalence of bacterial infections caused by longer stay in hospitals as well as immunocompromising chronic diseases that make patients prone to bacterial infections is expected to boost carbapenem-based antibiotics market growth.
- Currently, the carbapenem-based antibiotics market is dominated by ertapenem. However, tebipenem is expected to gain traction during the forecast period in terms of revenue.
- In terms of indication, pneumonia is expected to garner highest market share as compared to other bacterial infections owing to a large patient pool.
For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=4425
“ Recently, FDA granted Qualified Infectious Disease Product (QIDP) to sulopenem as well as tebipenem for new indications, which is further expected to broaden the growth prospect of the carbapenem-based antibiotics market,” says the Fact.MR Analyst.
Strategic Expansion by Dominant Players Benefiting Market
The carbapenem-based antibiotics market is dominated by top three players including Merck Co. & Inc., Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. These leading players in the carbapenem-based antibiotics market contribute around 80% to 90% revenue share. Clinical stage companies such as Spero Therapeutic Inc. and Iterum Therapeutics Inc. with the launch of their novel carbapenem-based antibiotics are expected to acquire significant market space. In October 2017, Spero Therapeutics, Inc. and Meiji Seika Pharma Co., Ltd. announced an exclusive licensed partnership for its carbapenem-based antibiotic named SPR994 (tebipenem).
For comprehensive insights on this market adoption, ask an analyst here- https://www.factmr.com/connectus/sample?flag=AE&rep_id=4425
In a similar development, Sumitomo Dainippon Pharma in June 2017, announced a partnership with Zuellig Pharma for sales of carbapenem-based antibiotic meropenem in five countries of Southeast Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583